anti-PD-1/anti-TIM-3 bispecific antibody LB1410
Term · Oncology and biomedicine · MLC-T-ONC-010982
A recombinant humanized bispecific antibody directed against both the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1/anti-TIM-3 bispecific antibody LB1410 simultaneously targets and binds to both TIM-3 and PD-1 expressed on certain T cells. This blocks the interaction of TIM-3 with some of its physiologic ligands and prevents the activation of PD-1 by its ligands, programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. TIM-3, a transmembrane protein and immune checkpoint receptor, is often co-expressed with PD-1 on tumor-antigen-specific T cells. Dual checkpoint blockade of PD-1 and TIM-3 may enhance T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone.
| Identifier | MLC-T-ONC-010982 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | anti-PD-1/TIM-3 bispecific antibody LB1410; PD-1 x TIM-3 bispecific antibody LB1410 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-010982",
"term": "anti-PD-1/anti-TIM-3 bispecific antibody LB1410",
"field": "Oncology and biomedicine",
"definition": "A recombinant humanized bispecific antibody directed against both the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1/anti-TIM-3 bispecific antibody LB1410 simultaneously targets and binds to both TIM-3 and PD-1 expressed on certain T cells. This blocks the interaction of TIM-3 with some of its physiologic ligands and prevents the activation of PD-1 by its ligands, programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. TIM-3, a transmembrane protein and immune checkpoint receptor, is often co-expressed with PD-1 on tumor-antigen-specific T cells. Dual checkpoint blockade of PD-1 and TIM-3 may enhance T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone.",
"synonyms": [
"anti-PD-1/TIM-3 bispecific antibody LB1410",
"PD-1 x TIM-3 bispecific antibody LB1410"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/anti-pd-1-anti-tim-3-bispecific-antibody-lb1410/"
}
Record 2,112 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.